Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group

Fogelman et al., 2000 | J Clin Endocrinol Metab | Rct

Citation

Fogelman I, Ribot C, ... Reginster J Y. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. J Clin Endocrinol Metab. 2000-May;85(5):1895-900

Abstract

Our objective was to investigate the efficacy and tolerability of risedronate in postmenopausal women with low bone mass. Women with a mean lumbar spine T-score of -2 or less (n = 543) received 24 months of placebo or risedronate (2.5 or 5 mg/day). All received calcium (1 g/day). The principal outcome measures were bone mineral density (BMD) at the lumbar spine, femoral neck, and femoral trochanter. At 24 months, lumbar spine BMD increased from baseline by 4% with 5 mg risedronate and 1.4% in the 2.5-mg group, compared with no change with placebo. Efficacy was similar in women who were less than 5 yr and more than 5 yr postmenopausal. At 24 months, risedronate (5 mg) had also increased BMD at the femoral neck and trochanter, whereas BMD decreased in the placebo group. BMD increases were seen at all three sites with risedronate (5 mg) after only 6 months of therapy. Risedronate was well tolerated; upper gastrointestinal adverse events were similar to placebo. We conclude that risedronate (5 mg) increases BMD rapidly and effectively and is well tolerated in postmenopausal women with low bone mass, regardless of time since menopause.

Key Findings

We conclude that risedronate (5 mg) increases BMD rapidly and effectively and is well tolerated in postmenopausal women with low bone mass, regardless of time since menopause.

Outcomes Measured

Requires manual extraction

Population

Field	Value
Population	postmenopausal women
Sample Size	543
Age Range	See abstract
Condition	See abstract

MeSH Terms

Aged
Bone Density
Calcium
Calcium Channel Blockers
Double-Blind Method
Etidronic Acid
Europe
Female
Femur
Humans
Lumbar Vertebrae
Middle Aged
Osteoporosis, Postmenopausal
Placebos
Risedronic Acid
Time Factors

Evidence Classification

Level: Rct
Publication Types: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Vertical: manganese

Provenance

PMID: 10843171
DOI: (not available)
PMCID: Not in PMC
Verified: 2026-04-10 via PubMed E-utilities API

Source extracted via PubMed E-utilities API on 2026-04-10